Abstract
Objective
Restless legs syndrome (RLS) is a common sensorimotor disorder characterized by uncomfortable and unpleasant sensations in the legs that are relieved by movement. This study evaluated the prevalence of RLS in a consecutive series of cancer patients during chemotherapy and examined the relationship between presence of RLS and quality of life, anxiety, and depressive symptoms in these patients.
Methods
RLS was assessed according to the International RLS Study Group essential diagnostic criteria in two stages: a screening questionnaire first, followed by a sleep specialist–conducted structured diagnostic interview. The following questionnaires were administered: Functional Assessment of Cancer Therapy-General (FACT-G) for Quality-of-life (QoL) assessment; Hospital Anxiety and Depression Scale (HADS) to evaluate the levels of anxiety and depression; and Mini Mental Adjustment to Cancer Scale (Mini-MAC) to assess co** styles.
Results
A total of 257 patients were evaluated. Among them 56 were identified by the screening questionnaire to meet the criteria for RLS and 47 of whom were confirmed as affected by RLS after a structured interview, rendering a prevalence rate of 18.3%. RLS was significantly more frequent in women than men (23.7 vs. 11.8%; P = 0.01), and in patients receiving antineoplastic therapies for more than 3 months than their counterpart (21.8 vs. 10.8%; P = 0.03). Compared with those without RLS, patients with RLS had higher levels of anxiety (P = 0.0009) and depression (P = 0.001) and lower quality of life (P = 0.006). Sex-chemotherapy-duration-adjusted odds ratios of anxiety and physical well-being associated with RLS were 1.1 (95% CI 1.00–1.19; P = 0.04) and 0.7 (95% CI 0.43–1.01; P = 0.04), respectively.
Conclusions
The prevalence of RLS in cancer patients undergoing chemotherapy is 18.3%, about double of that expected in the general population. The occurrence of RLS is much more frequent in female patients and with longer-term chemotherapy. Cancer patients afflicted by RLS have significantly higher levels of anxiety and depression, and poorer quality of life especially in the physical well-being dimension. Recognition and treatment of RLS in cancer patients is an important target in clinical management and may improve quality of life and overall health outcomes in these patients.
Similar content being viewed by others
References
Sateia, M. J., & Lang, B. J. (2008). Sleep and cancer: Recent developments. Current Oncology Reports, 10, 309–318.
Lis, C. G., Gupta, D., & Grutsch, J. F. (2008). The relationship between insomnia and patient satisfaction with quality of life in cancer. Supportive Care in Cancer, 16, 261–266.
Broman, J. E., Mallon, L., & Hetta, J. (2008). Restless legs syndrome and its relationship with insomnia symptoms and daytime distress: Epidemiological survey in Sweden. Psychiatry and Clinical Neurosciences, 62, 472–475.
Montplaisir, J., Allen, R., Walters, S. A., Ferini-Strambi, L. (2005). Restless legs syndrome and periodic limb movements during sleep. In M. H. Kryger, T. Roth, W. C. Dement (Eds), Principles and practice of sleep medicine (pp. 839–852). Philadelphia: Elsevier-Saunders.
Allen, R. P., Picchietti, D., Hening, W. A., Trenkwalder, C., Walters, A. S., & Montplaisir, J. (2003). Restless legs syndrome: Diagnostic criteria, special considerations, and epidemiology: A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Medicine, 4, 101–119.
Earley, C. J. (2003). Restless legs syndrome. New England Journal of Medicine, 348, 2103–2109.
Atlas Task Force of the American Sleep Disorders Association. (1993). Recording and scoring of leg movements. Sleep, 16, 748–759.
Hening, W., Allen, R., Walters, A. S., Brown, T., & Montplaisir, J. (2003). Prevalence of restless legs syndrome (RLS) and impact of symptoms on the quality of life of sufferers. European Journal of Neurology, 10, S43.
Berger, K., Luedemann, J., Trenkwalder, C., John, U., & Kessler, C. (2004). Sex and the risk of restless legs syndrome in the general population. Archives of Internal Medicine, 164, 196–202.
Allen, R., Walters, A. S., Montplaisir, J., Hening, W., Myers, A., Bell, T. J., et al. (2005). Restless legs syndrome prevalence and impact: REST general population study. Archives of Internal Medicine, 165, 1286–1292.
Hening, W., Walters, A. S., Allen, R. P., Montplaisir, J., Myers, A., & Ferini-Strambi, L. (2004). Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: The REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Medicine, 5, 237–246.
Allen, R. P. (2007). Controversies and challenges in defining the etiology and pathophysiology of restless legs syndrome. American Journal of Medicine, 120, S13–S21.
Comella, C. L. (2002). Restless legs syndrome: Treatment with dopaminergic agents. Neurology, 58, S87–S92.
Davidson, J. R., MacLean, A. W., Brundage, M. D., & Schulze, K. (2002). Sleep disturbances in cancer patients. Social Science and Medicine, 54, 1309–1321.
Cella, D. F., Tulsky, D. S., Gray, G., et al. (1993). The functional assessment of cancer therapy scale: Development and validation of the general measure. Journal of Clinical Oncology, 11, 570–579.
Zigmond, A. S., & Snaith, R. P. (1983). The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica, 67, 361–370.
Watson, M., Law, M., dos Santos, M., Greer, S., & Baruch, J. (1994). Bliss J. The mini-MAC: Further development of the mental adjustment to cancer scale psychosoc oncol, 12, 33–46.
Grassi, L., Buda, P., Cavana, L., Annunziata, M. A., Torta, R., & Varetto, A. (2005). Styles of co** with cancer: The Italian version of the mini-mental adjustment to cancer scale. Psycho-Oncol, 14, 115–224.
Ferini-Strambi, L. (2007). RLS-like symptoms: Differential diagnosis by history and clinical assessment. Sleep Medicine, 2, S3–S6.
Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale, NJ: Lawrence Erlbaum Associates.
Korpacka, M. K., Matusiewicz, M., Diakowska, D., et al. (2009). Even a mild anemia is related to tumor aggressiveness mediated by angiogenic factors. Experimental Oncology, 31, 52–56.
Ekbom, K. A. (1960). Restless legs syndrome. Neurology, 10, 868–873.
Kushida, C., Martin, C., Nikam, P., Blaisdell, B., Wallenstein, G., Ferini Strambi, L., et al. (2007). Burdenof restless legs syndrome on health-related quality of life. Quality of Life Research, 16, 617–624.
Wittmack, T. (1861). Pathologie und Therapie der Sensibilitat-Neurosen. Leipzig: E. Schafer.
Picchietti, D., & Winkelmann, J. W. (2005). Restless legs syndrome, periodic limb movements in sleep, and depression. Sleep, 28, 891–898.
Cankurtaran, E. S., Ozalp, E., Soygur, H., et al. (2008). Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: Superiority over imipramine. Supportive Care in Cancer, 16, 1291–1298.
Rottach, K., Schaner, B., Kirch, M., et al. (2009). Restless legs syndrome as a side effect of second generation antidepressants. Journal of Psychiatric Research, 43, 70–75.
Acknowledgments
We thank Tracy Kuo, PhD, Stanford, CA for her help in editing the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ostacoli, L., Saini, A., Ferini-Strambi, L. et al. Restless legs syndrome and its relationship with anxiety, depression, and quality of life in cancer patients undergoing chemotherapy. Qual Life Res 19, 531–537 (2010). https://doi.org/10.1007/s11136-010-9614-8
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11136-010-9614-8